NEW YORK, Dec. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Ligand Pharmaceuticals Inc. (“Ligand”) (NASDAQ:LGND) between November 9, 2015 and November 14, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of California. To get more information go to:
http://www.zlk.com/pslra/ligand-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Ligand you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
First Western Ship Transits Strait of Hormuz Since Iran War Began
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Apple Turns 50: From Garage Startup to AI Crossroads 



